Table 1.
Patient characteristics of the study cohort
| Number | n = 10 | |
| Age (years), median (range) | 68.5 (28–83) | |
| Sex, n (%) | ||
| Male | 6 (60%) | |
| Female | 4 (40%) | |
| Smoking status, n (%) | ||
| Never | 2 (20%) | |
| Former or current | 8 (80%) | |
| Body weight (kg) | 56.4 ± 7.3 | |
| Body height (m) | 1.59 ± 0.1 | |
| Body mass index (kg/m2) | 22.4 ± 3.9 | |
| Histological type, n (%) | ||
| Adenocarcinoma | 7 (70%) | |
| Squamous cell carcinoma | 2 (20%) | |
| Adenosquamous carcinoma | 1 (10%) | |
| Mutation status, n (%) | ||
| EGFR | 1 (10%) | |
| EML4-ALK fusion | 1 (10%) | |
| ROS1 fusion | 1 (10%) | |
| Wild type or unknown | 7 (70%) | |
| Clinical stage, n (%) | ||
| IIIB or IV | 9 (90%) | |
| Recurrence | 1 (10%) | |
| Chemotherapy, n (%) | ||
| Platinum-based doublet chemotherapy | 8 (80%) | |
| Non-platinum chemotherapy | 2 (20%) | |
EGFR, epidermal growth factor receptor; EML4-ALK, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion; n, number of cases (% total cases); ROS1 fusion, c-ros oncogene 1 receptor tyrosine kinase fusion. Data are presented as the mean ± SD.